Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML(Pediatric AML) | withdrawn | Phase 1 | 0 | Elucida OncologyINDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06182410 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Aug 7, 2024 |
| NCT05898828 | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06335745 | PediCARE Health Equity Intervention in High-Risk Neuroblastoma | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Aug 5, 2024 | clinicaltrials |
| NCT01239108 | Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias | withdrawn | Phase 1 | 0 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy | withdrawn | Phase 2 | 0 | AdventHealthOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04231526 | Pembrolizumab in Early Stage Colon Cancer | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04955938 | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04508855 | Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)(MAFIC) | withdrawn | — | 0 | AHEPA University HospitalOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jul 26, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Immunocore LtdINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05515692 | Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Jul 23, 2024 | clinicaltrials |
| NCT06017271 | Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer | withdrawn | — | 0 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT05039931 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06370871 | Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | withdrawn | Phase 3 | 0 | Boehringer IngelheimINDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT05050305 | Marizomib Central Nervous System (CNS) | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 10, 2024 | clinicaltrials |
| NCT05364645 | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05690035 | Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05738161 | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma(MACOCUC-01) | withdrawn | Phase 1 | 0 | Insel Gruppe AG, University Hospital BernOTHER | 0 | Jul 5, 2024 | clinicaltrials |
| NCT05869994 | Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures | withdrawn | — | 0 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05204160 | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05408195 | E-Care Acceptability for Older People Undergoing Chemotherapy(ONCO-CHATBOT) | withdrawn | N/A | 0 | University Hospital, ToulouseOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT05736705 | Monopolar and Bipolar in Esophageal ESD | withdrawn | N/A | 0 | Baylor College of MedicineOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT05545969 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma(Neo PeLeMM) | withdrawn | Phase 2 | 0 | Melanoma Institute AustraliaOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04833959 | Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | withdrawn | Phase 1 | 0 | Stanford UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05740449 | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART A) | withdrawn | Phase 1 / Phase 2 | 0 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT02840227 | The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections | withdrawn | N/A | 0 | The Cleveland ClinicOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05567055 | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations | withdrawn | Phase 2 | 0 | Timothy Burns, MD, PHDOTHER | 0 | Jun 17, 2024 | clinicaltrials |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | withdrawn | Phase 2 | 0 | Northside Hospital, Inc.OTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | withdrawn | N/A | 0 | Medical University of GrazOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05082493 | A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas | withdrawn | Phase 1 | 0 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 0 | Jun 6, 2024 | clinicaltrials |
| NCT05572476 | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer(LURBIMUNE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT05568940 | Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids(eTAPE) | withdrawn | — | 0 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05309018 | Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML(LAMIPA) | withdrawn | — | 0 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT03955068 | Strict Classic Ketogenic Diet as a Therapy for Recurrent or Progressive and Refractory Brain Tumors in Children | withdrawn | N/A | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT02407613 | Efficacy of MR-HIFU Ablation of Breast Cancer | withdrawn | N/A | 0 | UMC UtrechtOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05411107 | Oral Iloprost for the Prevention of Lung Cancer In Former Smokers | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | withdrawn | N/A | 0 | The University of Tennessee, KnoxvilleOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT03122249 | Oncology Associated Symptoms & Individualized Strategies(OASIS) | withdrawn | N/A | 0 | Stephanie Gilbertson-WhiteOTHER | 1 | May 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2024source: clinicaltrials